[{"orgOrder":0,"company":"Provention Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Provention Bio and Vactech Announce Publication of Proof-of-Concept Data for a Preclinical Prototype of Coxsackievirus B Vaccine","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","url1":"","url2":"","graph1":"Vaccine","graph2":"Provention Bio"},{"orgOrder":0,"company":"Cure Pharmaceutical","sponsor":"Axiom Capital Management","pharmaFlowCategory":"D","amount":"$10.0 million","upfrontCash":"$4.0 million","newsHeadline":"CURE Pharmaceutical Closes $10 Million Financing","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"November 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Cure Pharmaceutical"},{"orgOrder":0,"company":"Antares Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Antares Pharma FDA Acceptance of IND Application for ATRS-1902","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Antares Pharma"},{"orgOrder":0,"company":"Biomea Fusion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biomea Fusion Announces Presentation of Lead Menin Inhibitor BMF-219 in Diabetes at ADA 82nd Scientific Sessions 2022","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Biomea Fusion"},{"orgOrder":0,"company":"SAB Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SAB Biotherapeutics Initiates IND-Enabling GLP Toxicology Study for SAB-142","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"SAB Biotherapeutics"},{"orgOrder":0,"company":"Biomea Fusion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biomea Fusion Announces FDA Clearance of Investigational New Drug (IND) Application for Covalent Menin Inhibitor BMF-219 in Type 2 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Biomea Fusion"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alnylam Submits CTA Application for ALN-KHK, an Investigational RNAi Therapeutic for the Treatment of Type 2 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Alnylam Pharmaceuticals"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
ALN-KHK is an investigational, subcutaneously administered RNAi therapeutic targeting ketohexokinase for the treatment of Type 2 diabetes mellitus (T2DM). The safety and efficacy of ALN-KHK have not been evaluated by the FDA, EMA, Health Canada, or any other health authority.
In animal models, BMF-219 has shown a very unique profile in preserving, reactivating and regenerating beta cells. BMF-219 was designed to specifically inhibit menin.
SAB-142 is fully-human therapeutic that may be administered multiple times without inducing immune-mediated reactions including immediate anaphylaxis or delayed serum sickness.
Biomea plans to initiate a Phase I/II clinical trial of lead menin inhibitor BMF-219 in diabetes in the second half of 2022, subject to submission and clearance of an investigational new drug (IND) application.
The active IND enables Antares to initiate a Phase 1 clinical study for ATRS-1902 for the treatment of acute adrenal insufficiency, known as adrenal crisis, in adults and adolescents, using a novel proprietary auto-injector platform to deliver hydrocortisone.
Funds will support the branding & product launch of Cure’s consumer products by newly acquired Sera Labs and the advancement of CURE’s clinical pharmaceutical pipeline
Publication results demonstrates that a preclinical prototype of Provention's polyvalent coxsackievirus B (CVB) vaccine, PRV-101, is well-tolerated, immunogenic and highly protective in relevant animal models.